Nelson Research's Dexan
Sandoz obtains U.S. and Canadian marketing rights to the irritable bowel syndrome product. Nelson noted that the final phase of clinical trials on Dexan was initiated this spring and an NDA is expected to be filed with FDA in 1986.
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.